A Phase 4 interventional study of Pneumococcal 13-valent Conjugate Vaccine and Trivalent Influenza Vaccine in Plasma Cell Neoplasm, sponsored by Emory University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Emory University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 38th largest by enrollment of the 386 interventional ones that give a count, is one of 9 that started in 2019, is one of 4 in phase 4, and was the 450th registered.
710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.
Browse Neoplasms, Plasma Cell studies →26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 185 · Phase 2 252 · Phase 3 41 · Phase 4 4
First in 1975; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 40 across 527 interventional studies indexed under Neoplasms, Plasma Cell.
Median enrollment 33 across the 386 interventional studies, 159 across the 42 observational. Of the 430 that completed or were terminated, 152 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 502 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.
Emory University has 2 studies filed under Neoplasms, Plasma Cell — fewer than ten, so there is no comparison to draw.
13 of the studies in Neoplasms, Plasma Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT01269593Memorial Sloan Kettering Cancer CenterPET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | 2026-12 |
| NCT05336383M.D. Anderson Cancer CenterPhase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | 2026-12-07 |
| NCT06271252OriCell Therapeutics Co., Ltd.A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | 2026-12-12 |
| NCT07052916Memorial Sloan Kettering Cancer CenterA Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | 2026-12-27 |
Add all 13 to your calendar (.ics) → With an account.
Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.
PRIMARY OBJECTIVES:
I. Demonstrate an absolute 25% increase in seroprotection, defined as hemagglutination antibody inhibition (HAI) > 40 against all strains, at week 21 in the experimental arm compared to the control arm.
II. Determine correlation between HAI, predefined risk of influenza-like illness (low, moderate, high), and progression-free survival (PFS).
EXPLORATORY OBJECTIVES:
I. Measurement of B \& T-cell subsets and flu-specific responses as a way of understanding immunosuppression in this patient population, correlating with influenza-like illness.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive trivalent influenza vaccine intramuscularly (IM) at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed for 4 weeks and then periodically for 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
Biological: Pneumococcal 13-valent Conjugate Vaccine · Biological: Trivalent Influenza Vaccine
Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
Biological: Pneumococcal 13-valent Conjugate Vaccine · Biological: Trivalent Influenza Vaccine
Given IM
Also known as: PCV13, Prevnar 13
Given IM
Also known as: Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV
Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)
HAI in blood at week 21 for all variants
Time frame: 21 weeks
| Milestone | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) |
|---|---|---|
| Started | 80 | 85 |
| Completed | 64 | 81 |
| Not completed | 16 | 4 |
HAI in blood at week 21 for all variants
| Participants | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) |
|---|---|---|
| Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) | 32 | 22 |
Collected over 1 year. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Trivalent Influenza Vaccine, Prevnar) | 3/80 (3.8%) | 0/80 (0%) | 0/80 (0%) |
| Arm II (Trivalent Influenza Vaccine, Prevnar) | 1/85 (1.2%) | 0/85 (0%) | 0/85 (0%) |
| Age, Categorical(Participants) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 46 | 47 | 93 |
| >=65 years | 34 | 38 | 72 |
| Age, Continuous(years) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| Mean | 61.7 ± 11.60 | 62.8 ± 9.68 | 62.35 ± 10.63 |
| Sex: Female, Male(Participants) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| Female | 37 | 30 | 67 |
| Male | 43 | 55 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 70 | 83 | 153 |
| Unknown or Not Reported | 8 | 1 | 9 |
| Race (NIH/OMB)(Participants) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 22 | 27 | 49 |
| White | 51 | 54 | 105 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 4 | 9 |
| Region of Enrollment(participants) | Arm I (Trivalent Influenza Vaccine, Prevnar) | Arm II (Trivalent Influenza Vaccine, Prevnar) | Total |
|---|---|---|---|
| United States | 80 | 85 | 165 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in May 2021, 18 months.
Results were first posted in Feb 2025, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine